Healthcare Private Equity Outlook: Takeaways From HPE Miami 2026

At McDermott Will & Schulte’s HPE Miami 2026 Conference, more than 2,000 healthcare founders, investors, advisors, and industry leaders gathered to examine the structural and policy forces reshaping the health and life sciences investment landscape.

As the event’s official knowledge partner, McKinsey & Company contributed to these discussions. Together with McDermott, they highlighted the key trends influencing how buyers and sellers are positioning transactions for 2026 and beyond.

Performance and Investment Considerations

Operational Execution Overtaking Financial Engineering

A live audience poll identified operational execution as the most important driver of near-term private equity performance. The traditional model—acquiring strong healthcare businesses and relying primarily on board-level strategy—is giving way to a more hands-on approach. Firms are now expected to bring deep operational expertise and actively drive improvements within portfolio companies.

Compliance And Quality Central To Value Creation

Compliance, quality management, and operational rigor are increasingly critical to investment success. In healthcare, regulatory oversight can significantly impact enterprise value and deal outcomes. Issues such as billing errors, quality failures, or enforcement actions can disrupt growth plans and delay exits.

Talent And Leadership Key Investment Criteria

Given the complexity of multi-site healthcare platforms, execution depends on strong leadership beyond the executive team. Investors are placing greater emphasis on talent diligence, evaluating leadership depth, succession planning, and the scalability of management teams alongside financial performance.

Strategic Focus Drives Platform Success

Top-performing healthcare platforms tend to concentrate on a limited number of high-impact priorities rather than pursuing too many initiatives at once. Strategic discipline is emerging as a defining characteristic of successful investments.

Creative Deal Structures Bridging Valuation Gaps

Differences in valuation expectations between buyers and sellers continue to slow transactions. In response, investors are adopting more flexible deal structures, including corporate carve-outs, management partnerships, phased acquisitions, and milestone-based pricing tied to future performance.

Rebounds and Regulatory Readiness

Technology And AI Fueling Deal Activity

Nearly half (47%) of surveyed participants identified health IT and AI-enabled services as the primary drivers of deal momentum. Investors are increasingly targeting platforms with scalable technology and clear pathways for integrating AI into clinical and operational workflows.

Pharma Pipeline Needs Reviving M&A Activity

Pharmaceutical companies are playing a major role in the recovery of life sciences M&A. With patent expirations projected to erase nearly $300 billion in revenue by 2028, companies are turning to acquisitions, partnerships, and licensing agreements to replenish their pipelines.

Drug Development Becoming Global And Faster-Paced

Innovation activity is accelerating in Asia, particularly in China and South Korea, driving cross-border partnerships. At the same time, shorter product life cycles—due to biosimilars, pricing pressures, and regulatory shifts—are forcing companies to accelerate development timelines and engage external partners earlier in the process.

Key Actions For Healthcare Investors and Operators

McDermott identified several practical steps for investors and platform operators:

• Develop a comprehensive value creation playbook that embeds compliance and regulatory oversight into core operations, including:
  • Clinical quality monitoring
  • Billing and coding compliance
  • Regulatory risk management
  • Data governance and privacy
  • Process improvements supported by automation and AI
• Integrate these priorities during diligence, not just post-acquisition, to better underwrite value creation opportunities.
• Build deep operational capabilities as a competitive advantage. Firms with targeted expertise in specific operational areas are better positioned to drive efficiencies and generate outsized returns.
• Prioritize compliance and quality management as foundational elements of value creation strategies.
• Invest in leadership development pipelines, especially below the C-suite, to ensure consistency and scalability across multi-site platforms.
• Adopt flexible transaction structures and prepare early for exits, particularly in a market shaped by valuation gaps, regulatory complexity, and heightened diligence requirements.

Source: mondaq